Affymax

Affymax rises on analyst view of anemia drug
Yahoo/AP
Sat, 03/3/12 - 11:09 am
Affymax
peginesatide
Epogen
anemia
Merck, Pfizer, Bristol-Myers, Affymax, Chelsea Therapeutics Face Key Dates in March
Minyanville
Wed, 02/29/12 - 04:52 pm
Merck
Pfizer
Bristol-Myers Squibb
Chelsea Therapeutics
Affymax
Astex
JNJ
Discovery Labs
Ariad Pharmaceuticals
NeurogesX
Amgen
The 9 Biotechs With The Highest Growth Expectations
Seeking Alpha
Sat, 02/4/12 - 03:30 pm
Theratechnologies
SeraCare Life Sciences
Gentium
Curis
BioDelivery Sciences
Amarin
Affymetrix
Affymax
Vertex Pharmaceuticals
Past Bouncers And Others Biotech Plays Ready To Move
Seeking Alpha
Thu, 01/26/12 - 02:15 pm
Aeterna Zentaris
Affymax
Ampio
Bacterin International Holdings
GelTech
Cel-Sci
Ista
Inovio
Lpath
Nabi
Novavax
PharmAthene
US FDA panel gives positive opinion to Affymax's anaemia drug peginesatide
Pharmabiz
Sat, 12/10/11 - 01:23 pm
Affymax
peginesatide
Takeda
chronic kidney disease
Affymax: A Soaring Biotech With Room to Run
Motley Fool
Fri, 12/9/11 - 11:43 am
Affymax
peginesatide
Affymax Rises After Winning Panel’s Backing for Anemia Drug
Bloomberg
Thu, 12/8/11 - 11:32 am
anemia
FDA
advisory panels
Affymax
peginesatide
Affymax Jumps Most in 16 Months on FDA Review of Anemia Drug
Bloomberg
Mon, 12/5/11 - 01:34 pm
Affymax
FDA
anemia
chronic kidney disease
JNJ
Amgen
peginesatide
December Catalysts for Drug and Biotech Stocks
Minyanville
Sat, 12/3/11 - 11:11 am
Pfizer
Aveo Pharmaceutical
Affymax
Amgen
Antares Pharma
Celgene
ONYX Pharmaceuticals
Seattle Genetics
Micromet
YM BioSciences
Regeneron
BioSante
Biotech Stock Mailbag: Affymax
The Street
Sat, 12/3/11 - 11:01 am
Affymax
Affymax Gears Up for its Make-or-Break Moment, As Anemia Drug Faces FDA Scrutiny
Xconomy
Fri, 11/18/11 - 11:50 am
anemia
FDA
advisory panels
Affymax
peginesatide
Affymax and Takeda Report Additional Analyses of Peginesatide Phase 3 Studies in Dialysis Patients at the American Society of Nephrology’s Kidney Week 2011
Yahoo/BusinessWire
Sat, 11/12/11 - 12:16 pm
peginesatide
chronic kidney disease
dialysis
Affymax
Takeda
9 Biotech Stocks Trading At Steepest Discount To Target Price
Seeking Alpha
Sun, 10/30/11 - 12:40 pm
Inhibitex
Affymax
Alnylam
Incyte
Ziopharm
Array Biopharma
Ariad Pharmaceuticals
Xoma
Complete Genomics
FDA sets date to review Affymax anemia drug
Yahoo/AP
Mon, 10/24/11 - 11:36 am
FDA
Affymax
anemia
peginesatide
chronic kidney disease
Biotech Calendar: 2011-12 FDA Drug Approvals
TheStreet.com
Thu, 08/11/11 - 12:37 pm
biotech
drug approvals
FDA
Eyelea
Regeneron
Dendreon
Provenge
NuPathe
Zelrix
Adcetris
Seattle Genetics
Soliris
Alexion
Dapagliflozin
AstraZeneca
Bristol-Myers Squibb
EXPAREL
Pacira
Roche
Zelboraf
Iluvien
Alimera
Bio-T-Gel
Teva Pharmaceuticals
BioSante
Zevalin
Spectrum
ruxolitinib
Incyte
Novartis
Pfizer
crizotinib
Antares
Anturol
Bydureon
Amlyin
Eli Lilly
Alkermes
AZ-004
Alexza
Corlux
Corcept Therapeutics
Affymax
Takeda
peginesatide
Levadex
MAP Pharmaceuticals
Affymax, Takeda seek approval of peginesatide in dialysis patients with chronic kidney disease
Yahoo/AP
Tue, 05/31/11 - 12:39 pm
chronic kidney disease
Takeda
Hematide/peginesatide
Affymax
Affymax in $50M stock sale
bizjournals.com
Sat, 03/19/11 - 10:00 am
Affymax
Affymax shares jump on analyst upgrade
bizjournals.com
Sat, 03/12/11 - 01:20 pm
Affymax
Affymax rallies on CEO appointment
Market Watch
Sat, 01/8/11 - 11:49 am
Affymax
Biotech Calendar: Key Dates for December
TheStreet.com
Tue, 11/30/10 - 09:20 am
Delcath
Arena Pharmaceuticals
RXi Pharmaceuticals
Cell Therapeutics
Amgen
Incyte
Celgene
Corcept Therapeutics
Affymax
Targacept
Exelixis
Orexigen
ONYX Pharmaceuticals
Seattle Genetics
MannKind
Alimera
AstraZeneca
Human Genome Sciences

Pages